Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Fig. 3

Kaplan–Meier and ROC analyses of patients with OSC in different age cohorts, grouping based on their ages at initial diagnosis: ≤ 50 (N = 127, 23.05%), 51–60 (N = 178, 32.30%), > 60 (N = 246, 44.65%). a Kaplan–Meier analysis with two-sided log-rank test was performed to estimate the differences in OS between the low-risk and high-risk patients. b ROC curves of the five-DNA methylation signature were used to demonstrate the sensitivity and specificity in predicting the OS of patients

Back to article page